The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Mylan Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, for the delivery of fluticasone inhalers. The contract has a base period of one year from August 1, 2021 to July 31, 2022, with four one-year option periods, for a total potential value of $366,011,941.10. This IDC will provide fluticasone inhalers to the VA, Bureau of Prisons, and Indian Health Service through the VA Pharmaceutical Prime Vendor program.
The original solicitation, RFP 36E79721R0021, was issued by the VA National Acquisition Center to procure inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) inhalers with no set-aside. The contract aims to establish an uninterrupted source of supply for these critical pharmaceutical products used to treat respiratory conditions in veteran, federal inmate, and Native American patient populations served by these government healthcare systems.
Generated 12/20/24, 9:09 AM